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Objective: Long-term success of revascularization procedures is limited by recurrent stenosis, a reduction in vascular lumen
area that results from neointimal hyperplasia. Inhibitors of the renin-angiotensin system, such as losartan, have potential
to prevent recurrent stenosis; however, to date, efficacy has not been demonstrated in either animal models or human
beings. While we have previously reported that treatment with a satisfactory dose may be an important element in
obtaining efficacy, oral delivery cannot achieve the required concentration. We therefore tested the ability of losartan to
restrict neointimal hyperplasia after local delivery of an elevated dose in a fibrin glue.
Methods: The porcine saphenous artery was subjected to balloon angioplasty. Losartan (25mol/mL) was applied directly
to the adventitial surface of the injured vessel after mixing with 1.0 mL of Tisseel. Neointimal formation was quantified
after 14 days with morphometry, and immunologic staining was used to monitor expression of proteins associated with
cell proliferation, migration, and phenotypic modulation.
Results: A statistically significant decrease of 82% (n  5) in neointimal area was obtained with losartan, and cell
proliferation, as defined by proliferating cell nuclear antigen (PCNA) expression, was inhibited by 97%. Reduced cyclin
A expression in losartan-treated vessels confirmed that cell cycle progression was blocked; however, the presence of
cytokeratin 8 and tenascin in the media and neointima of injured vessels, regardless of treatment, suggested that losartan
does not restrict phenotypic modulation. Inhibition of MT1-MMP (MMP-14) expression by losartan indicated that this
inhibitor likely suppresses cell migration as well.
Conclusions: These data demonstrate that losartan can effectively prevent recurrent stenosis when delivered locally with a
fibrin glue such as Tisseel. Our results also indicate that losartan may operate by interfering with the expression of
proteins required for cell cycle progression and migration. (J Vasc Surg 2004;40:130-7.)
Clinical Relevance: Release of angiotensin II in response to vascular injury may promote neointimal hyperplasia, because
this hormone can stimulate smooth muscle cell proliferation and migration. This study demonstrates that local
application of an angiotensin receptor antagonist, losartan, to the site of injury can effectively prevent neointimal
hyperplasia after balloon angioplasty. Application of losartan to the perivascular surface of the injured vessel in a surgical
fibrin glue enabled delivery of a dose that exceeds the maximum attainable, via a systemic delivery route. The glue also
served as a depot from which the drug was slowly released over time. Treatment with losartan may be a viable approach
for controlling neointimal hyperplasia at locations (eg, grafts) that are accessible during a surgical procedure.Arterial obstruction due to atherosclerosis is the pri-
mary cause of both coronary artery and peripheral arterial
disease. To combat this problem, various revascularization
procedures have been developed, and both balloon angio-
plasty and bypass graft surgeries have been remarkably
effective in improving symptoms such as angina, claudica-
tion, and limb-threatening ischemia, as well as quality of
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doi:10.1016/j.jvs.2004.02.031130life. However, the long-term success of these procedures is
limited by recurrent stenosis, a reduction in vascular lumen
area at the site of intervention, which can occur within 6 to
12 months of revascularization.1,2
Recurrent stenosis results from both a compensatory
decrease in total vessel diameter and formation of a neoin-
tima.3 Three processes contribute to the formation of a
neointimal lesion: vessel recoil due to stretching and tear-
ing of the vessel; adherence of platelets to the subendothe-
lial layers of the vessel after denudation, followed by platelet
degranulation and the release of mitogens; and smooth
muscle cell (SMC) migration to the intima followed by
proliferation, and recruitment of monocytic cells. While
each process is typically discussed as a separate entity,
histologic evidence suggests that the entire arterial struc-
ture undergoes coordinated remodeling.4 Furthermore,
vascular remodeling apparently depends on phenotypic
modulation of vascular SMCs, defined as the switch from a
quiescent, contractile cell population to one capable of
both proliferation and synthesis of abundant extracellular
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ing the revascularization procedure.
The link between angiotensin II (AngII) and vascular
remodeling is compelling.5 AngII is rapidly released in
response to vascular stress,6 and, as a mitogen, promotes
both migration and proliferation.7,8 Inflammatory activa-
tion of SMCs is also triggered by AngII, as indicated by
increased production of interleukin-69 and monocyte che-
moattractant protein-1.10 Inasmuch as the extent of leuko-
cyte activation correlates with the degree of stenosis after
angioplasty,11 it is plausible that synthesis of AngII by
infiltrating cells prolongs the vascular healing process and
thus amplifies the size of the resultant neointima. Conse-
quently, systemic administration of an AngII receptor an-
tagonist would be expected to inhibit recurrent stenosis.
Only limited improvements have been noted in studies
using this approach. Nevertheless, an investigation of losar-
tan with an organ culture system suggests that the imped-
iment to achieving a reduction in recurrent stenosis might
be dose-related.12
Direct application of losartan to a site of vascular injury
was achieved with the aid of a surgical fibrin glue, Tisseel.
This dual-component glue enables reconstitution of the
lyophilized material with losartan, which becomes trapped
within the coagulum that forms on mixing of the compo-
nents, and thus forms a depot from which losartan is
released. We observed that losartan, delivered locally at a
dose that exceeds the maximum level obtainable with any
other route, is capable of significantly reducing the intimal
hyperplasia induced by balloon angioplasty.
MATERIAL AND METHODS
Balloon angioplasty. After approval from the local
research ethics committee, male castrated farm pigs (25-30
kg) were anesthetized and maintained on isoflurane
throughout the procedure. With the pig supine, the left
femoral artery was exposed and the bifurcation of the
saphenous artery identified. The saphenous artery was then
exposed for a length of 5 cm. A mixture of nitroglycerin and
papaverine was applied to the vessel, and the area was
covered with a saline solution–soaked sponge to keep the
tissues moist. The right saphenous artery was also exposed,
treated with vasodilators, and covered with a sponge. The
left femoral artery was clamped, and an arteriotomy was
made at the bifurcation. A standard angioplasty balloon
(3.0  20 mm; Scimed) was inserted through the arteriot-
omy and passed at least 2 cm into the saphenous artery. The
balloon was inflated for 1 minute, then deflated and care-
fully removed, and the arteriotomy was closed with 6.0
polypropylene (Prolene) suture. Tisseel (1.0 mL) was ap-
plied to the surface of the vessel, from the arteriotomy to a
point beyond the site of balloon inflation. The right saphe-
nous artery was treated identically. The incision, including
the deep fascia, was then closed with 3.0 polyglactin 910
(Vicryl) suture, and the skin was stapled to close the wound.
Pigs were given antibiotic agents for 5 days, and were
euthanized 14 days after the procedure.Fibrin glue. Tisseel (0.5-mL kit; Baxter) was prepared
according to the manufacturer’s instructions. In brief, the
contents of the thrombin vial were resuspended with 0.5
mL of CaCl2 solution, and the sealer proteins in the second
vial were reconstituted with 0.5 mL of aprotinin solution.
Both vials were warmed at 37°C for 5 minutes, with con-
stant stirring to ensure complete dissolution. When the
surgery was near completion, the contents of each vial were
drawn into separate syringes and attached to the applicator
device, and the entire 1.0-mL volume was delivered to the
surface of the closed vessel. The incision was closed when
coagulum had formed. Losartan (25 mmol/L) was dis-
solved in the CaCl2 solution before thrombin resuspension.
Treatment conditions. Tisseel was applied to both
the left and right saphenous arteries of the test animals after
balloon angioplasty. One artery received Tisseel without
losartan; the other received Tisseel with losartan. Applica-
tion of test article to right and left vessels was randomized
between animals, and surgical staff were blinded to the
treatments.
Morphometry. After pig euthanization, the saphe-
nous arteries were exposed and carefully removed. Each
artery was divided into two pieces, flash frozen in optimal
cutting temperature embedding medium, and stored at
80°C. Transverse sections 7 m thick were prepared on
glass slides and placed into Streck tissue fixative for 10
minutes, washed extensively with phosphate-buffered sa-
line solution, then stained for 1 minute in Lee’s methylene
blue, which enhances the visibility of the internal elastic
lamina, cell nuclei, and muscle tissues. The slides were
serially washed with water, 70% ethanol, and water before
being air dried. Images were captured with a DAGE-MTI
CCD camera, and the neointimal and medial areas were
used to calculate the neointimal index: intimal area/medial
area.12
Immunohistologic detection of protein markers of
cell proliferation, migration, and phenotype. Trans-
verse sections (7 m) mounted on Superfrost microscope
slides (Fisher Scientific) were fixed in cold acetone at
20°C for 10 minutes and allowed to air dry. Nonspecific
protein binding sites were blocked by incubation with 3%
bovine serum albumin or Tris-buffered saline with 0.1%
Triton X-100 for 1 hour at room temperature. All antibod-
ies were diluted in 1% bovine serum albumin or TBS-T and
incubated with the sections for 1 hour at room tempera-
ture. Sections were subsequently washed with TBS-T, then
incubated with Cy3-conjugated secondary antibody (1:400
dilution) for 1 hour. Sections were counterstained with
Hoescht 33342 (nuclear-specific stain) for 1 minute to
identify individual cells, then mounted with Crystal/
Mount (Biomedia). Images were captured with a DAGE-
MTI CCD camera. Primary antibodies specific for prolifer-
ating cell nuclear antigen (PCNA; DAKO; diluted 1:100),
cyclin A (NeoMarkers; 1:50), cytokeratin 8 (Oncogene
Science; 1:10), tenascin (Chemicon; 1:100), and MT1-
MMP (Chemicon; 1:100) were used in this study.
Organ culture. Angioplasty of the porcine left ante-
rior descending coronary artery from hearts obtained from
d E.
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and culture of the vessel segments was conducted as de-
scribed.12 Vessel segments were incubated with varying
concentrations of candesartan for 14 days, then embedded
in JB-4 resin and sectioned (thickness, 1-2 m). Nonin-
jured and balloon-injured vessels without candesartan
treatment were used as control. Morphometry was used to
determine the neoinitimal index.
Elution of compounds from fibrin glue. Losartan
(25 mmol/L) or candesartan (10 mmol/L) was incorpo-
rated into Tisseel (1.0 mL), as described, with candesartan
dissolved in dimethyl sulfoxide before its addition to the
aprotinin solution. Each Tisseel preparation was placed into
one well of a six-well culture dish. Tisseel without either
compound served as the control for these experiments.
Three replicates were used for each condition. Saline solu-
tion (4.0 mL) was used to wash the coagulum. Subse-
quently the coagulum was covered with saline solution (4.0
mL), and 25-L aliquots were removed over 24 hours.
Fig 1. Effect of perivascular losartan delivery on neoint
were subjected to balloon angioplasty, and subsequently
Tisseel with losartan (25 mmol/L) were randomly appl
14-day recovery period, sectioned, and stained with Lee
neointimal lesion are shown for noninjured control vesse
with losartan treatment (C). Morphometry was used to c
data are presented as mean  SE (n  5). Effect of t
measuring the neointimal index obtained after balloon-in
(E). Morphologic data are presented as mean SE (n
(*) and balloon-injured (#) vessels are indicated in D anThymidine incorporation was measured after addition of
the aliquots to cultures of SMCs.12 The incorporation
obtained with the control samples was set to 100%. Inhibi-
tion was calculated relative to the respective control value
obtained at each time point.
Data analysis. Proliferation was quantified by count-
ing the number of PCNA-positive cells in relation to total
cell number as indicated with Hoescht 33342 counterstain.
Analysis of numerical data (PCNA staining, neointimal
hyperplasia, thymidine incorporation) was conducted by
personnel blinded to treatment details, and decoding oc-
curred only after all analyses were completed. Analysis of
variance was used to compare treatment means.12 Statistical
significance was assumed at P  .05.
RESULTS
Losartan reduces neointimal formation in vivo. Vi-
sual examination of stained saphenous artery sections
showed that angioplasty induced formation of a significant
formation after angioplasty. Porcine saphenous arteries
coated with 1.0 mL of Tisseel. Tisseel without agent and
the right or left vessels. Vessels were harvested after a
thylene blue for analysis. Lumen size and presence of a
, balloon-injured vessels (B), and balloon-injured vessels
ate the neointimal index (intimal area/medial area) (D);
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Arteries that were exposed to losartan, however, showed a
marked reduction in neointimal size (Fig 1, C). Quantifi-
cation of the neointimal index showed that there was a
statistically significant reduction of 82% in neointimal size
(Fig 1, D). No effect, positive or negative, was observed
when vehicle alone was applied to a balloon-injured vessel
(Fig 1, E), demonstrating that the reduction in neointimal
formation was due to losartan treatment. These data indi-
cate that losartan is capable of preventing neointimal for-
mation if applied directly to the vessel surface at a high
concentration.
Losartan inhibits proliferation post-angioplasty. Im-
munohistologic staining showed that uninjured arteries did
not express PCNA (Fig 2, A). In contrast, there was an
obvious increase in PCNA staining after balloon angio-
plasty, primarily within the neointima (Fig 2, B). Significant
intimal staining was evident immediately adjacent to the
internal elastic lamina, suggesting that this region was the
primary site of cell activation. Treatment with losartan
attenuated the PCNA expression induced at angioplasty
(Fig 2, C). Quantification of the number of cells expressing
PCNA under these three conditions confirmed the visual
evidence, and showed that losartan decreased PCNA stain-
Fig 2. Effect of losartan treatment on proliferating cel
angioplasty. Vessel sections were immunologically stained
33342 (blue) to visualize cell nuclei. A, Representative n
sartan-treated balloon-injured vessels. D, compilation of
groups. Data are presented as mean  SE. Significant d
vessels subjected to balloon angioplasty () are indicateing by 97% (Fig 2, D). The effect of losartan on cell cycle
progression was verified with staining for cyclin A. Cyclin A
was not detected in control vessel segments (Fig 3, A),
whereas balloon angioplasty induced cyclin A expression
within the neointima (Fig 3, B). Treatment with losartan
inhibited cyclin A expression (Fig 3, C). These data confirm
that losartan has a major effect on SMC proliferation that
correlates with the observed decrease in neointimal
formation.
Matrix metalloproteinase expression is prevented
by losartan. Expression of MT1-MMP (MMP-14), a pro-
teolytic enzyme that is induced by vascular injury and
regulates activation of the basement membrane degrading
enzyme MMP-2,13 was monitored to determine whether it
was affected by losartan treatment. No MT1-MMP was
detected after immunologic staining of uninjured vessels
(Fig 4, A); however, MT1-MMP was visible in vessels that
had been subjected to balloon angioplasty (Fig 4, B).
Furthermore, MT1-MMP was localized to the region
(both medial and intimal) bordering the internal elastic
lamina, the site most active in cell migration. The absence
of MT1-MMP in treated vessels (Fig 4, C) suggests that
losartan may prevent cell migration in addition to inhibit-
ing cell proliferation.
ear antigen (PCNA) expression in response to balloon
CNA (red). Sections were counterstained with Hoescht
jured control vessels. B, Balloon-injured vessels. C, Lo-
A-positive cells detected in each of the three treatment
nces (P  .05) from uninjured control vessels (*) andl nucl
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notype. The effect of losartan treatment on phenotypic
modulation was examined by staining vessel sections for
two markers of the synthetic phenotypic, cytokeratin-8 (an
intermediate filament protein) and tensascin (an extracellu-
lar matrix protein associated with inflammation and injury).
Neither cytokeratin-8 nor tenascin were detected in unin-
jured arteries (Fig 5, A and D). After balloon angioplasty,
however, strong expression of both proteins was evident in
the neointimal region (Fig 5, B and E). In the presence of
losartan there was a decline in the general intensity of
cytokeratin-8 staining; however, this reduction appears re-
lated to the decrease in neointimal size (Fig 5, C). Unlike
the uninjured vessel, cytokeratin-8 was visible in the few
intimal and subintimal cells that were visible. There was also
Fig 3. Cyclin A expression in injured vascular tissues treated with
losartan. Vessel sections were incubated with anti–cyclin A anti-
body. A, Representative noninjured control vessels. B, Balloon-
injured vessels. C, losartan-treated balloon-injured vessels. m, Me-
dial layer; n, neointima; l, lumen; arrow, internal elastic lamina.significant cytokeratin staining within the medial region. A
similar pattern of expression was seen with tenascin (Fig 5,
F). These data indicate that losartan inhibits SMC prolifer-
ation without blocking phenotypic modulation after vascu-
lar injury.
Are there viable alternatives to losartan? To explore
the possibility that other AngII type 1 receptor antagonists
could be delivered with fibrin glue, we tested candesartan,
an antagonist that is reportedly more potent than losartan.
In an organ culture experiment candesartan completely
prevented neointimal formation at a concentration of 1
mol/L (Fig 6, A). Inasmuch as 10 mol/L of losartan
was required to achieve similar inhibition,12 candesartan is
at least 10 times more effective than losartan in this exper-
imental system.
Fig 4. Expression of MT1-MMP in vessels after angioplasty and
treated with losartan. Vessel sections were incubated with anti-
MT1-MMP antibody. A, Representative noninjured control ves-
sels. B, Balloon-injured vessels. C, losartan-treated balloon-in-
jured vessels. m, Medial layer; n, neointima; l, lumen; arrow,
internal elastic lamina.
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compound (in dimethyl sulfoxide) was suspended in the
aprotinin solution used to dissolve the sealer proteins.
While soluble to this stage, visual evidence suggested that
the solvent was excluded on formation of the coagulum. An
in vitro experiment was therefore conducted to determine
the amount of candesartan incorporated into the coagu-
lum. Tisseel was mixed with either losartan or candesartan
and placed into individual wells of multiwell tissue culture
dishes. The coagulum was washed to remove all unincor-
porated material. It was then submersed in saline solution
for 24 hours. Aliquots were removed at specific times, and
elution of losartan or candesartan from Tisseel was detected
with a bioassay based on cell growth inhibition. These data
revealed that about 90% of the losartan was incorporated
into the coagulum (Fig 6, B). However, elution of losartan
from the coagulum was completed within 4 hours. In
contrast, more than 90% of the candesartan was excluded
from the coagulum (Fig 6, C). These data suggest that the
limited solubility of candesartan in aqueous solutions
makes it unlikely that sufficient candesartan can be incor-
Fig 5. Expression of cytokeratin and tenascin in the pres
stained for either cytokeratin-8 (A-C) or tenascin (D-E)
visualize cell nuclei. Noninjured control vessels (A an
balloon-injured vessels (C and F). m, Medial layer; n, nporated into Tisseel to achieve a concentration that will
exhibit efficacy in vivo. Drug delivery with Tisseel may
therefore be restricted to compounds that exhibit greater
water solubility.
DISCUSSION
This study reports that local application of losartan can
reduce intimal hyperplasia in response to balloon angio-
plasty in vivo when 25 mol/L (25 mol in 1.0 mL), an
amount incompatible with systemic delivery, is applied
directly to the adventitial surface of a vessel. The current
investigation also demonstrates the potential therapeutic
utility of fibrin glue as a vehicle for delivery of small mole-
cules. In particular, it is possible to introduce water-soluble
compounds into Tisseel during reconstitution of the lyoph-
ilized components (thrombin and a sealer protein mix of
factor XIII, fibrinogen, plasminogen, and plasmafibronec-
tin) and retain the compound at the site of application,
because the coagulum sets rapidly (60 s) and no free
liquid remains.
f losartan after balloon angioplasty. Vessel sections were
ions were counterstained with Hoescht 33342 (blue) to
. Balloon-injured vessels (B and E). Losartan-treated
ma; l, lumen; arrow, internal elastic lamina.ence o
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interventions rather than angioplasty, we nevertheless
chose balloon angioplasty for this investigation, because
the uniform injury that is produced is favorable to morpho-
logic analysis. Likewise, selection of the saphenous artery
was based on easy access. In addition, a small (diameter, 2-3
mm) muscular artery rapidly produces a significant neoin-
tima in response to injury. The extensive intima obtained
(Fig 1, B) also enabled us to use a 2-week treatment period
that paralleled the original organ culture study.12 This time
period was advantageous because resorption of fibrin glue
requires approximately 10 days,14 thus ensuring complete
release of the applied losartan had occurred. While we
cannot comment on the release kinetics in vivo obtained in
this study, we determined that the coagulum is not a barrier
to diffusion (Fig 6, B). Nevertheless, within tissue, elution
from fibrin glue occurs over several days.15
The release interval is a critical property for attaining
efficacy, because delivery of the agent must occur over an
extended period. For example, in organ culture studies
successful prevention of recurrent stenosis could be ob-
tained only when an inhibitor was continuously present for
4 to 7 days (unpublished data). This observation concurred
with Steele et al,16 who recommended a treatment period
of 4 to 7 days on the basis of temporal progression of
recurrent stenosis in pig carotid arteries in vivo. Thus
Tisseel may be an acceptable medium for local delivery,
because it addresses the two requirements of a practical
delivery system: physical delivery to the site and release
Fig 6. Assessment of candesartan for treatment of n
formation in organ culture (A). Porcine coronary arterie
were cultured in vitro for 14 days. Media contained the
period. Morphologic assessment of intimal and medial a
and Methods). Data are presented as mean SE (n 8 fo
and untreated balloon-injured (A) vessel samples show
concentrations of candesartan. Significant differences (P
balloon angioplasty () are indicated. Tisseel (1.0 mL),
of candesartan (C), was prepared in a six-well culture dish
(4.0 mL) for 24 hours. Elution of losartan and candesarta
inhibitory activity present in the initial rinse (pre) and in s
the Tisseel. The degree of inhibition was determined re
procured from a parallel preparation of Tisseel that cont
mean  SE (n  3 for each time point).kinetics necessary to ensure efficacy.17 At the same time, the
experiment did not examine the suitability of Tisseel for
sustained inhibition of recurrent stenosis. A longer term
study will therefore be necessary to determine whether
delivery for a maximum of 10 days with Tisseel is sufficient
to obtain permanent inhibition or simply delays onset of
hyperplasia. However, even if Tisseel is rapidly exhausted of
drug, as we observed in vitro (Fig 6, B), this approach could
be used as an adjunct with systemic delivery. Locally applied
losartan would reduce neointimal formation immediately
(2 weeks) after injury, and an orally administered AngII
type 1 receptor antagonist could be used to suppress the
factors that stimulate hyperplasia after this period.
In addition to assessing a novel delivery method for
treating recurrent stenosis, we evaluated the efficacy of the
AngII type 1 receptor antagonist losartan. Our previous
organ culture study had shown that a sufficiently high
concentration could successfully prevent neointimal forma-
tion in vitro.12 Nevertheless, it was recognized that sys-
temic delivery could not reach these concentrations in vivo.
When mixed with Tisseel, a concentration of 25 mmol/L
(25 mol/mL) was attainable. This concentration of losar-
tan had no deleterious effects on the surrounding tissues
(Fig 1), confirming the lack of cytotoxicity previously re-
ported for this compound.18 Nevertheless, this approach
may be limited to compounds that are more water soluble
than candesartan, a much more potent inhibitor of intimal
hyperplasia19 (Fig 6, A). This restriction will make it nec-
essary to individually test the compatibility of fibrin glues
mal hyperplasia. Effect of candesartan on neointimal
e subjected to balloon angioplasty, and vessel segments
ated concentration of candesartan for the entire 14-day
as used to calculate the neointimal index (see Material
h condition), with results for both uninjured control (N)
ddition to balloon-injured vessels treated with varying
5) from uninjured control (*) and vessels subjected to
ining either 25 mmol/L of losartan (B) or 10 mmol/L
coagulum was rinsed, then covered with saline solution
the coagulum was quantified by measuring the growth
s acquired at 0, 1, 2, 4, 8, and 24 hours after submersing
to the thymidine incorporation obtained with aliquots
neither losartan nor candesartan. Data are presented aseointi
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cause many of these compounds are more lipophilic than
losartan.
To examine the mechanism by which losartan restricted
neointimal lesion formation, vessel segments were immu-
nologically stained for specific markers of cell proliferation,
migration, and phenotypic state. This approach enabled us
to monitor localized expression of these proteins under
conditions in which the amount of intimal tissue was highly
variable; consequently, label intensity could not be accu-
rately used to indicate a change in expression. Cell prolif-
eration was diminished with losartan treatment according
to the level of PCNA and cyclin A expression (Figs 2 and 3).
Furthermore, quantification of PCNA staining showed
there was a 97% decrease in cells expressing PCNA, a value
that corresponds closely with the 82% decrease in neointi-
mal index. Although cell migration was not measured
directly, injury-induced expression of MT1-MMP was de-
creased in losartan-treated vessels (Fig 4). MT1-MMP has
been identified as a key factor in MMP-2 activation,13 and
MMP-2 is essential for penetration of the internal elastic
lamina by medial SMCs.20 Accordingly, MT1-MMP is
considered indispensable for SMC migration. These data
suggest that losartan decreases neointimal hyperplasia by
interfering with both proliferation and migration. On the
other hand, continued expression of cytokeratin-8 and
tenascin after losartan treatment suggests that losartan does
not block conversion of the smooth muscle phenotype.
Consequently, the positive actions of losartan must be
directed at a process that is activated during or subsequent
to phenotypic modulation. Identification of this process
may provide additional opportunity for development of
therapeutically active agents capable of inhibiting recurrent
stenosis.
Fibrin glue can be used to deliver an anti-restenosis
agent at a dose capable of reducing neointimal formation.
While this approach may be useful for treating recurrent
stenosis after angioplasty, as in this study, adventitial deliv-
ery with a fibrin glue is incompatible with angioplasty,
because access to the vessel is required. Rather, fibrin glue is
more appropriate for vascular graft surgery, in which the
relevant vessels are exposed. Even so, our experiments
indicate that this approach has clinical potential, and the
positive results obtained in this limited evaluation should
provide an impetus to develop compounds exhibiting anti-
restenosis activity that are compatible with fibrin glue or
similar technologies.
REFERENCES
1. Califf RM, Fortin DF, Frid DJ, Harlan WR, Ohman EM, Bengtson JR,
et al. Restenosis after coronary angioplasty: an overview. J Am Coll
Cardiol 1991;17:2B-13B.2. Schainfeld RM. Potential emerging therapeutic strategies to prevent
restenosis in the peripheral vasculature. Catheter Cardiovasc Intervent
2002;56:421-31.
3. Dangas G, Fuster V. Management of restenosis after coronary interven-
tion. Am Heart J 1996;132:428-36.
4. Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Wong C, et al.
Arterial remodeling after coronary angioplasty: a serial intravascular
ultrasound study. Circulation 1996;94:35-43.
5. Rosendorff C. The renin-angiotensin system and vascular hypertrophy.
J Am Coll Cardiol 1996;28:803-12.
6. Li Q, Muragaki Y, Ueno H, Ooshima A. Stretch-induced proliferation
of cultured vascular smooth muscle cells and a possible involvement of
local renin-angiotensin system and platelet-derived growth factor
(PDGF). Hypertens Res 1997;20:217-23.
7. Su EJ, Lombardi DM, Siegal J, Schwartz SM. Angiotensin II induces
vascular smooth muscle cell replication independent of blood pressure.
Hypertension 1998;31:1331-7.
8. Bell L, Madri JA. Influence of the angiotensin system on endothelial and
smooth muscle cell migration. Am J Pathol 1990;137:7-12.
9. Han Y, Runge MS, Brasier AR. Angiotensin II induces interleukin-6
transcription in vascular smooth muscle cells through pleiotropic acti-
vation of nuclear factor-kappa B transcription factors. Circ Res 1999;
84:695-703.
10. Chen XL, Tummala PE, Olbrych MT, Alexander RW, Medford RM.
Angiotensin II induces monocyte chemoattractant protein-1 gene ex-
pression in rat vascular smooth muscle cells. Circ Res 1998;83:952-9.
11. Tanaka H, Sukhova GK, Swanson SJ, Clinton SK, Ganz P, Cybulsky
MI, et al. Sustained activation of vascular cells and leukocytes in the
rabbit aorta after balloon injury. Circulation 1993;88:1788-1803.
12. Wilson DP, Saward L, Zahradka P, Cheung PK. Angiotensin II receptor
antagonists prevent neointimal proliferation in a porcine coronary artery
organ culture model. Cardiovasc Res 1999;42:761-72.
13. Jenkins GM, Crow MT, Bilato C, Gluzband Y, Ryu WS, Li Z, et al.
Increased expression of membrane-type matrix metalloproteinase and
preferential localization of matrix metalloproteinase-2 to the neointima
of balloon-injured rat carotid arteries. Circulation 1998;97:82-90.
14. Basu S, Marini CP, Bauman FG, Shirazian D, Damiani P, Robertazzi R,
et al. Comparative study of biological glues: cryoprecipitate glue, two-
component fibrin glue, and “French” glue. Ann Thorac Surg 1995;60:
1255-62.
15. Wong C, Inman E, Spaethe R, Helgerson S. Fibrin-based biomate-
rials to deliver human growth factors. Thromb Haemost 2003;89:
573-82.
16. Steele PM, Chesebro JH, Stanson AW, Holmes DRJ, Dewanjee MK,
Badimon L, et al. Balloon angioplasty: natural history of the pathophys-
iological response to injury in a pig model. Circ Res 1985;57:105-12.
17. Brieger D, Topol E. Local drug delivery systems and prevention of
restenosis. Cardiovasc Res 1997;35:405-13.
18. Spence SG, Cukierski MA, Manson JM, Robertson RT, Eydelloth RS.
Evaluation of the reproductive and developmental toxicity of the AT1-
selective angiotensin II receptor antagonist losartan in rats. Teratology
1995;51:383-97.
19. Oparil S. Newly emerging pharmacologic differences in angiotensin II
receptor blockers. Am J Hypertens 2000;13(suppl):S18-24.
20. Pauly RR, Passaniti A, Bilato C, Monticone R, Cheng L, Papadopoulos
N, et al. Migration of cultured vascular smooth muscle cells through a
basement membrane barrier requires type IV collagenase activity and is
inhibited by cellular differentiation. Circ Res 1994;75:41-54.
Submitted Jul 30, 2003; accepted Feb 22, 2004.
Available online Apr 14, 2004.
